Global ADHD Medication Shortage to Persist
The ongoing global shortage of ADHD medications is now forecasted to continue throughout 2026. The supply crisis for drugs like methylphenidate and amphetamine formulations has been described as the "most significant" in recent memory, with increased prescribing authority in some regions worsening the issue by boosting demand amid limited supply.
- The shortage, which began in late 2022 with manufacturing delays for Adderall, has expanded to include other stimulant medications like Ritalin, Concerta, and Vyvanse. This is due to a combination of factors, including increased global demand, manufacturing and supply chain issues, and strict regulatory quotas on the production of controlled substances. - A significant factor contributing to the increased demand is a rise in ADHD diagnoses, particularly among adults. Prescriptions for stimulant medications have risen by approximately 45% in the last decade. The temporary lifting of requirements for in-person visits to prescribe these medications during the pandemic also contributed to the surge in demand. - The U.S. Drug Enforcement Administration (DEA) sets annual production quotas for the active ingredients in stimulant medications to prevent misuse. While the DEA increased production quotas for d-amphetamine (the active ingredient in Adderall) and methylphenidate (the active ingredient in Ritalin and Concerta) in the fall of 2025, these increases may not be sufficient to resolve the shortages. - Pharmaceutical companies have reported difficulties in sourcing the active pharmaceutical ingredients (APIs) needed to produce these medications, creating bottlenecks in the global supply chain. In 2022, manufacturers only sold 70% of the volume of amphetamines allocated by the DEA's quota, leaving a billion potential doses unproduced. - The impact on patients is significant, leading to treatment disruptions that can worsen ADHD symptoms, affect academic and work performance, and increase the risk of co-occurring mental health issues like anxiety and depression. Some individuals have been forced to switch medications, travel long distances to find pharmacies with stock, or go without their medication altogether. - In response to the shortages, some pharmaceutical companies are creating direct-to-patient programs to improve access to their specific ADHD medication brands. Additionally, the FDA and DEA have encouraged manufacturers with unused production quotas to relinquish them so other companies can increase production.
